Illumina Partners With PREMIA To Expand CGP

Illumina Taiwan and Precision Medicine Asia (PREMIA) announced on Jan. 8, 2026 a strategic partnership to expand comprehensive genomic profiling (CGP) access across the Chang Gung Memorial Hospital (CGMH) system. The agreement aims to build an Asia-wide clinical-genomic oncology database, leveraging CGMH’s scale—serving about 2.7 million patients and running over 300 industry-sponsored trials—to support precision oncology and translational research. CGP was added to Taiwan’s NHI in May 2024.